文献速递免疫规划传染病防控与疫情报告

瑞典斯德哥尔摩县与芬兰2017年1月基于登记监测的65岁及以上人群季节性流感疫苗效果季节中期实时估计

Mid-season real-time estimates of seasonal influenza vaccine effectiveness in persons 65 years and older in register-based surveillance, Stockholm County, Sweden, and Finland, January 2017.
PubMed 文献 · Euro Surveill · 2017-01-01

瑞典斯德哥尔摩县和芬兰在2016/17流感季前建立基于人群队列的登记监测系统,实时评估实验室确诊流感的疫苗效果(VE)。两地甲型H3N2流感早期流行于2016年第52周达峰;第48至50周65岁及以上人群VE约为50%,至2017年第2周在斯德哥尔摩和芬兰分别降至28%和32%。

要点

  • 第48至50周65岁及以上人群流感VE约为50%,至2017年第2周斯德哥尔摩降至28%、芬兰降至32%。
  • 接种者中68%的样本属3C.2a1亚支(含T135K)或3C.2a亚支(含T131K和R142K),该比例在研究期间上升。
  • 这些氨基酸替换可能参与病毒抗原变化并部分解释VE下降,老年人疫苗免疫原性较差也可能是原因之一。

核心结论

  • 65岁及以上人群流感VE在第48至50周约为50%,至2017年第2周在斯德哥尔摩和芬兰分别降至28%和32%。
  • 敏感性分析考虑接种后时间后,未能显示明确的VE下降,无论按日历周还是按接种后时间。
  • 这些氨基酸替换可能参与病毒抗原变化并部分解释观察到的VE下降,老年人疫苗免疫原性较差也可能是另一原因。
  • 需要改进的流感疫苗,尤其是针对老年人。

研究设计与样本

  • 瑞典斯德哥尔摩县和芬兰在2016/17流感季开始前建立基于登记系统的实时疫苗效果监测,采用基于人群的队列研究。

主要发现

  • 两地甲型H3N2流感早期流行于2016年第52周达峰。
  • 第48至50周65岁及以上人群VE约为50%,至2017年第2周在斯德哥尔摩和芬兰分别降至28%和32%。
  • 敏感性分析考虑接种后时间后,未能显示明确的VE下降,无论按日历周还是按接种后时间。
  • 接种者中68%的样本属3C.2a1亚支(含血凝素T135K替换,64%)或3C.2a亚支(含血凝素T131K和R142K替换,36%),该比例在研究期间上升。

局限性

  • 敏感性分析考虑接种后时间后,未能显示明确的VE下降,无论按日历周还是按接种后时间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Systems for register-based monitoring of vaccine effectiveness (VE) against laboratory-confirmed influenza (LCI) in real time were set up in Stockholm County, Sweden, and Finland, before start of the 2016/17 influenza season, using population-based cohort studies. Both in Stockholm and Finland, an early epidemic of influenza A(H3N2) peaked in week 52, 2016. Already during weeks 48 to 50, analyses of influenza VE in persons 65 years and above showed moderately good estimates of around 50%, then rapidly declined by week 2, 2017 to 28% and 32% in Stockholm and Finland, respectively. The sensitivity analyses, where time since vaccination was taken into account, could not demonstrate a clear decline, neither by calendar week nor by time since vaccination. Most (68%) of the samples collected from vaccinated patients belonged to the 3C.2a1 subclade with the additional amino acid substitution T135K in haemagglutinin (64%) or to subclade 3C.2a with the additional haemagglutinin substitutions T131K and R142K (36%). The proportion of samples containing these alterations increased during the studied period. These substitutions may be responsible for viral antigenic change and part of the observed VE drop. Another possible cause is poor vaccine immunogenicity in older persons. Improved influenza vaccines are needed, especially for the elderly.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Hergens MP, Baum U, Brytting M, et al. Mid-season real-time estimates of seasonal influenza vaccine effectiveness in persons 65 years and older in register-based surveillance, Stockholm County, Sweden, and Finland, January 2017. Euro Surveill. 2017. PMID: 28251891. doi:10.2807/1560-7917.ES.2017.22.8.30469

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。